<DOC>
	<DOCNO>NCT01221610</DOCNO>
	<brief_summary>A prospective , multi-centre , randomize control , First Man study assess safety performance coat Passeo-18 Lux Paclitaxel release PTA Balloon Catheter vs. uncoated balloon catheter patient stenosis occlusion femoropopliteal artery .</brief_summary>
	<brief_title>BIOLUX P-I First Man Study</brief_title>
	<detailed_description />
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Vascular Diseases</mesh_term>
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<mesh_term>Arteriosclerosis</mesh_term>
	<criteria>1 . Age ≥ 50 year , 2 . Informed consent sign patient prior randomization 3 . Single sequential de novo restenotic lesion ( stenosis ≥ 70 % diameter reduction occlusion ) femoropopliteal artery ≥ 30 mm ≤ 200 mm long 4 . Rutherford Class 2 5 target limb 5 . Reference Vessel Diameter ( RVD ) 3 7 mm , base visual estimation 6 . Inflow free flowlimiting lesion ( &lt; 50 % stenosis ) confirm angiography . Patients flowlimiting inflow lesion ( &gt; 50 % stenosis ) include lesion treat successfully index procedure 7 . At least one nonoccluded crural vessel ( eg without significant stenosis ) angiographically document runoff foot 8 . Successful wire cross lesion 9 . Willingness comply specify followup evaluation 10 . Male negative pregnancy test woman childbearing age 1 . Comorbid condition limit life expectancy ≤ 1 year 2 . Patient currently participate another clinical trial 3 . Lesions untreatable PTA interventional technique 4 . The target stenosis locate distal stenosis ≥ 50 % pretreated drug coating could get lose cross proximal lesion 5 . Thrombus target vessel , document angiography 6 . Target lesion severely calcify , document angiography 7 . Prior bypass surgery target vessel 8 . Previously implant stent target lesion 9 . Treatment bifurcation require 10 . Planned amputation target limb 11 . Flowlimiting ( &gt; 50 % DS ) Inflow lesion proximal target lesion , leave untreated 12 . Failure obtain &lt; 30 % residual stenosis preexist haemodynamically significant ( &gt; 50 % DS ) inflow lesion ipsilateral iliac proximal SFA . ( DEB DES allow treatment inflow lesion ) 13 . Additional hemodynamically relevant proximal distal lesion stenosis ≥ 50 % , except iliac artery , exclude . Iliac artery lesion treatment successful residual stenosis ≤ 30 % 14 . Haemorrhagic diathesis another disorder gastrointestinal ulceration cerebral circulatory disorder restrict use platelet aggregation inhibitor therapy anticoagulation therapy 15 . Phenprocoumon intake 16 . Impaired renal function ( creatinine ≥ 2.0 2.5 mg/dl ) , accord investigator assessment 17 . Known allergy contrast medium adequately control premedication 18 . Allergy , intolerance hypersensitivity Paclitaxel structurally related compound and/or delivery matrix nButyryl trinhexyl citrate ( BTHC )</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Stenosis</keyword>
	<keyword>Occlusions</keyword>
	<keyword>SFA</keyword>
	<keyword>PTA</keyword>
	<keyword>POBA</keyword>
	<keyword>DRB</keyword>
</DOC>